Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
 - EconoTimes)
WARREN, N.J., April 07, 2016 -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today announced that the U.S. Patent and Trademark Office (USPTO) has upheld the validity of all challenged claims in U.S. Patent No. 8,765,167 (the ‘167 patent). The challenges to the ‘167 patent were asserted in four Inter Partes Review (IPR) proceedings brought by BioDelivery Sciences International, Inc. (Nasdaq:BDSI) (“BDSI”) against MonoSol Rx.
One IPR was denied institution in May 2015, and the rehearing request on that IPR was denied by the USPTO in November of 2015. Even more significantly, the three remaining IPR challenges were decided in final written decisions issued by the USPTO on March 24, 2016, wherein the USPTO upheld the validity of the claims in the ‘167 patent, which is entitled “Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions.” The ‘167 patent has a priority date as far back as 2001, as well as additional priority in 2005.
“The PTO’s confirmation of the validity of our ‘167 patent is an important victory for MonoSol Rx and for our proprietary, patented PharmFilm technology,” said A. Mark Schobel, Chief Innovation and Technology Officer of MonoSol Rx. “Now that these issues relating to the ‘167 patent have been decided, we will continue to aggressively assert this patent and others against those companies that infringe our intellectual property. At the same time, MonoSol Rx looks forward to quickly and reasonably resolving all outstanding and potential infringement matters related to the claims in the ‘167 and related patents. We remain confident in the strength of our entire portfolio of intellectual property and in the pioneering work we have done in the area of film-based drug delivery.”
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products. MonoSol Rx 's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.
Contact MonoSol Rx Jessica Patel [email protected] The Ruth Group Lee Roth [email protected] (646) 536-7012
